Loading
Scribe Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$391.3M
6 insiders bought €62.6M of shares over the last 90 days, the latest by AH Bio Fund II, L.P., filed 29 Jul 2026.
Scribe Therapeutics, Inc.: what insiders have been doing
Scribe Therapeutics, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). 7 insiders have disclosed 12 filings since 24 October 2025.
Every open-market trade in the period is a purchase: 7 purchases worth €49.4M, from 5 insiders, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €30.7M, bought by Aghazadeh Behzad and made public on 28 July 2026 (8.5% of market cap). Among those who bought: 3 senior executives, 1 major shareholder and 1 finance chief.
In the case of 7 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last purchase on record was published on 29 July 2026, which is 87 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 12 filings, this issuer sits below that mark. Looking back to 2026, when coverage begins, insiders filed 7 purchases and no sales.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
13
Thresholds
n/a
Buy Volume
€49M
7 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleBehzad Aghazadeh3 buys
David Parrot2 buys
AH Bio Fund II, L.P.1 buy
Carl L. Gordon1 buy
Orbimed Advisors LLC1 buy
Svetlana Lucas1 buy
Since the insiders bought
- +49.7%Entry US$20.40 · Close at T+30 US$30.54
- +49.7%Entry US$20.40 · Close at T+30 US$30.54
- +54.9%Entry US$18.36 · Close at T+30 US$28.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$20.67
Analyst consensus
4 analysts1.00/5
US$50.00Target US$57.00(+176%)US$60.00
Income statement
RevenueUS$51.2M
EBITDA-US$18.1M-35% margin
Net income-US$21.8M-97.0% margin
Valuation
PER (forward)-5.7x
Balance sheet & cash
Market capUS$391.3M
Total debtUS$41.4M
Free Cash Flow-US$46.5M
Profitability & ownership
% insiders10.7%
% institutions54.5%
Last declaration on 29 July 2026
Declarations13 total
12,511 sharesCommon StockSEC:0001739090-26-000010:0
348,825 sharesCommon StockSEC:0000947871-26-000734:0
2,051,742 sharesCommon StockSEC:0001231919-26-000813:0
697,650 sharesCommon StockSEC:0001231919-26-000813:1
348,825 sharesCommon StockSEC:0000947871-26-000733:0
1,000,000 shares@ US$15.003.66% mcap100.0% of flowCommon StockSEC:0000947871-26-000733:1
Canonical exit: 25 Oct 2026 (T+90)
333,333 shares@ US$15.001.22% mcap100.0% of flowCommon StockSEC:0001231919-26-000813:2
Canonical exit: 25 Oct 2026 (T+90)
1,000,000 shares@ US$15.003.66% mcap100.0% of flowCommon StockSEC:0000947871-26-000734:1
Canonical exit: 25 Oct 2026 (T+90)
2,333,333 shares@ US$15.008.55% mcap96.5% of flowCommon Stock, par value $0.0001 per shareSEC:0000902664-26-003270:0
Canonical exit: 22 Oct 2026 (T+90)
50,000 shares@ US$22.310.27% mcap3.1% of flowCommon Stock, par value $0.0001 per shareSEC:0000902664-26-003270:1
Canonical exit: 22 Oct 2026 (T+90)
7,905 shares@ US$18.250.035% mcap0.4% of flowCommon Stock, par value $0.0001 per shareSEC:0000902664-26-003270:2
Canonical exit: 26 Oct 2026 (T+90)
3,000 shares@ US$15.000.011% mcap100.0% of flowCommon StockSEC:0001781292-26-000007:0
Canonical exit: 21 Oct 2026 (T+90)
1,333 shares@ US$15.000.0049% mcap100.0% of flowCommon StockSEC:0002127908-26-000004:0
Canonical exit: 21 Oct 2026 (T+90)
13 of 13 declarations
About Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. is a biotechnology company focused on developing gene therapies. It utilizes advanced technologies to design innovative treatments for genetic diseases.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
